Gately M K, Glaser M, McCarron R M, Dick S J, Dick M D, Mettetal R W, Kornblith P L
Acta Neurochir (Wien). 1982;64(3-4):175-97. doi: 10.1007/BF01406052.
Whereas substantial evidence indicates that the majority of glioma patients make humoral immune responses to their own tumours, the evidence that glioma patients make significant cellular immune responses is more tenuous and controversial. In order to study those properties of human gliomas that might contribute to their ability to escape cell-mediated immune attack, we have examined the ability of cultured human glioma cells to elicit allogeneic cytolytic lymphocyte responses in vitro. Five of ten glioma lines were unable to elicit allogeneic cytolytic lymphocyte responses in mixed lymphocyte-tumour cultures, despite the presence of serologically detectable alloantigens on the surface of the glioma cells. Analysis of the reasons why certain glioma lines failed to stimulate cytolytic lymphocyte responses revealed three distinct mechanisms by which human gliomas may escape cellular immune attack: 1. a defect in immunogenicity which can be overcome by "help" from an allogeneic mixed lymphocyte reaction, 2. the secretion of a protective mucopolysaccharide coat, and 3. the production of macromolecular immunosuppressive substance(s). The implications of these findings for the immunotherapy of human gliomas are discussed.
尽管大量证据表明大多数胶质瘤患者对自身肿瘤产生体液免疫反应,但胶质瘤患者产生显著细胞免疫反应的证据却较为薄弱且存在争议。为了研究人类胶质瘤可能有助于其逃避细胞介导免疫攻击的那些特性,我们检测了培养的人类胶质瘤细胞在体外引发同种异体溶细胞淋巴细胞反应的能力。在混合淋巴细胞 - 肿瘤培养中,十个胶质瘤细胞系中有五个无法引发同种异体溶细胞淋巴细胞反应,尽管胶质瘤细胞表面存在血清学可检测的同种异体抗原。对某些胶质瘤细胞系未能刺激溶细胞淋巴细胞反应的原因分析揭示了人类胶质瘤可能逃避细胞免疫攻击的三种不同机制:1. 免疫原性缺陷,可通过同种异体混合淋巴细胞反应的“辅助”来克服;2. 分泌保护性粘多糖包膜;3. 产生大分子免疫抑制物质。讨论了这些发现对人类胶质瘤免疫治疗的意义。